On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year Dr Dana Hilt, CMO, commented:“There remains an enormous unmet med ...